Highlights
– Five years of treat‑to‑target urate‑lowering therapy (T2T‑ULT) markedly reduced serum uric acid (sUA) and ultrasound‑detected monosodium urate (MSU) deposits in the NOR‑Gout cohort.
– At 5 years, 71.2% achieved sUA <360 μmol/L; double contour and tophi resolved in 83.4% and 63.2% of affected sites respectively, with first MTP often demonstrating the greatest change.
– Only 16% reported gout flares in the previous year; those patients had higher residual sUA and ultrasound crystal burden, reinforcing the clinical relevance of sustained low sUA.
